Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

Part of paid clinical trials in East Hanover, New Jersey.

Sponsor
Novartis
Study ID
NCT00006269
Phase
PHASE3
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Octreotide may be effective in preventing diarrhea that is caused by treatment with irinotecan. PURPOSE: Randomized phase III trial to study the effectiveness of octreotide in preventing diarrhea in patients who are receiving irinotecan for metastatic colon cancer.

Key Dates

Start date
Dec 31, 1999
Status verified
May 2012
Primary completion
Dec 31, 1999

Study Design

Enrollment
89 participants (actual)
Primary purpose
SUPPORTIVE_CARE

Locations (2)

FacilityCityStateZIPSite coordinators
Novartis Pharmaceuticals CorporationEast HanoverNew Jersey07936-
TheradexPrincetonNew Jersey08543-

Find similar trials in East Hanover, NJ

By condition
Colorectal cancer
By specialty
OncologyGI oncology
By research site
Novartis Pharmaceuticals Corporation· East Hanover, NJTheradex· Princeton, NJ

Related Studies